Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Oncolytics Biotech: Pelareorep’s Clinical Progress Faces a Critical Funding Test

Oct 15, 2026 | Team Kalkine
Oncolytics Biotech: Pelareorep’s Clinical Progress Faces a Critical Funding Test
Image source: shutterstock

  • ONCY:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Oncolytics Biotech Inc

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biopharmaceutical company developing pelareorep, an intravenous immunotherapy designed to activate immune responses and make tumors more susceptible to cancer treatments. Supported by encouraging findings across several cancer studies, the company is advancing pelareorep alongside chemotherapy and/or checkpoint inhibitors, primarily targeting metastatic gastrointestinal cancers..

Latest Business Development


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…